Pharmafile Logo
Pharmafocus logo
Advanced Search

HIV

Showing 15 posts of 193 posts found.

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

News

FDA relaxes blood donation regulations for MSM

May 12, 2023
Medical Communications FDA, HIV, HIV/AIDS, blood donation

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …

News

GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs

June 22, 2021
Manufacturing and Production GSK, HIV, ViiV Healthcare

ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …

News

New HIV prevention drug application submitted to FDA

May 5, 2021
Research and Development FDA, HIV

ViiV Healthcare have initiated a rolling submission of a new drug application (NDA) with the FDA for their long-acting HIV …

News
gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

News
landing-hero-images1

ViiV presents positive long-term data for combined HIV treatment

March 8, 2021
Sales and Marketing HIV, ViiV Healthcare

ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …

News
landing-hero-images1

ViiV’s HIV drug Rukobia gets EC marketing authorisation

February 9, 2021
Manufacturing and Production HIV, ViiV

The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …

News
scripps_research_web_03-18-19_t670

Scripps Research and IAVI report positive findings from HIV vaccine Phase I trial

February 4, 2021
HIV

Scripps Research and IAVI have returned positive Phase I results in their hunt for a HIV vaccine, detecting a targeted …

News
landing-hero-images1

ViiV’s long-acting HIV drug Cabenuva gets FDA approval

January 22, 2021
Medical Communications HIV, ViiV Healthcare

The FDA has approved ViiV’s Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in …

News
viiv

ViiV and Chelsea & Westminster Hospital launch digital service for HIV patients

January 18, 2021
Sales and Marketing HIV, ViiV Healthcare

Global specialist HIV company ViiV Healthcare and Chelsea and Westminster Hospital NHS Foundation Trust have launched a new service, Klick, …

News
landing-hero-images1

ViiV gets EU approval for children’s HIV treatment

January 13, 2021
Research and Development EU, HIV, ViiV

ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission for Tivicay (dolutegravir) 5mg dispersible …

News
1070297_viiv-healthcare-office-16

ViiV Healthcare announces authorisation of Europe’s first long-acting HIV injection

December 21, 2020
Sales and Marketing GlaxoSmithKline, HIV, ViiV

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced the authorisation of Europe’s first complete long-acting …

News
gilead-sciences

Gilead’s lenacapavir meets primary goal in heavily treated and multidrug resistant HIV-1

November 19, 2020
Research and Development Gilead, HIV, pharma

Gilead has pulled back the curtain on promising new data for its long-acting HIV-1 capsid inhibitor lenacapavir for heavily treated …

News
hiv_on_macrophage

Viiv Healthcare’s cabotegravir effective in HIV prevention in women

November 9, 2020
Sales and Marketing AIDS, HIV

Viiv Healthcare’s cabotegravir is more effective in preventing HIV in women than the oral standard of care, according to an …

News
gilead-sciences

Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients

October 22, 2020
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023